Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage III prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 62 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Modifications to Radical Prostatectomy in Improving Outcomes in Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 11-096, NCI-2011-02377, NCT01407263
Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PrTK03, NCI-2012-01912, NCT01436968
A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR102931, NCI-2013-02187, 2012-004322-24, ARN-509-003, NCT01946204
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
Magnetic Resonance Spectroscopic Imaging in Finding Tumors in Patients with Stage I-III Prostate Cancer Planning to Undergo Prostate Surgery
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 2006-0516, NCI-2011-00517, PC061612, NCT00464724
Talazoparib in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Vaccine Therapy in Treating Patients With Prostate Cancer Previously Treated With Surgery or Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-070, NCI-2011-01874, NCT00970203
Prostatic Acid Phosphatase-Sargramostim Fusion Protein or Sargramostim in Treating Patients with Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO 08801, NCI-2011-00965, H-2008-0073, NCT01341652
Antiandrogen Therapy with or without Axitinib before Surgery in Treating Patients with Previously Untreated Prostate Cancer with Known or Suspected Lymph Node Metastasis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2015-01711, NCI-2011-02749, NCT01409200
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 and over
Trial IDs: Pro00041857, NCI-2013-00581, 00041857, Amd020_Pro00041857, NCT01763944
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 125513, NCI-2013-02375, CC#125513, NCT01787331
Pazopanib Hydrochloride Followed by Surgery in Treating Patients with High-Risk Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI63129, NCI-2014-00453, 63129, PZP116921, NCT01832259
Docetaxel and Lycopene in Treating Patients with Hormone-Resistant Prostate Cancer Not Previously Treated with Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: UCI 10-11, NCI-2011-00037, 2010-7765, NCT01882985
Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-000714, NCI-2015-01448, EMT13001, NCI-2014-02414, NCT01990196
Start Over